Literature DB >> 31938208

miR-34a inhibits tumorigenesis of NSCLC via targeting SIRT6.

Libo Ruan1,2,3, Jun Chen2, Litao Ruan4, Anjun Tan2, Ping Wang1,2,3.   

Abstract

Non-small cell lung cancer (NSCLC) remains the leading cause of deaths around the world. Therefore, improving the diagnostic and treatments of NSCLC are urgently needed. The microRNA-34a (miR-34a) and SIRT6 are associated with NSCLC. miR-34a is downregulated in three NSCLC cells lines (A549, H460, and H1299). The functions of SIRT6 in NSCLC are controversial. Some reports have shown that SIRT6 is downregulated in NSCLC cells, while other reports have shown that SIRT6 is upregulated in NSCLC tissues as well as SIRT6 overexpression is associated with the poor prognosis of NSCLC. SIRT6 is a direct target of miR-34a in human keratinocytes (HKCs). However, the relationship between SIRT6 and miR-34a in NSCLC has not been investigated. In this study, we found that the SIRT6 was upregulated in NSCLC tissues while miR-34a was downregulated in NSCLC tissues compared with those in their normal counterparts. Overexpression of miR34a or downregulation of SIRT6 promoted A549 cells apoptosis, cell cycle arrest in vitro and further inhibited the tumor formation in vivo. SIRT6 was indeed the target gene of miR-34a, which was proved by the luciferase reporter data. Therefore, we conclude that SIRT6 was the target gene of miR-34a in NSCLC. miR-34a acted as a cancer suppressor in NSCLC via targeting the SIRT6. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); SIRT6; microRNA-34a (miR-34a)

Year:  2018        PMID: 31938208      PMCID: PMC6958161     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  34 in total

1.  The dual role of sirtuins in cancer.

Authors:  Laia Bosch-Presegué; Alejandro Vaquero
Journal:  Genes Cancer       Date:  2011-06

2.  SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer.

Authors:  Yoko Azuma; Takehiko Yokobori; Akira Mogi; Bolag Altan; Toshiki Yajima; Takayuki Kosaka; Ryoichi Onozato; Ei Yamaki; Takayuki Asao; Masahiko Nishiyama; Hiroyuki Kuwano
Journal:  J Surg Oncol       Date:  2015-07-15       Impact factor: 3.454

3.  International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

Authors:  Susan S Devesa; Freddie Bray; A Paloma Vizcaino; D Max Parkin
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

4.  Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway.

Authors:  Eui-Jun Kim; Yong-Sung Juhnn
Journal:  J Biol Chem       Date:  2015-02-24       Impact factor: 5.157

5.  p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.

Authors:  N R Christoffersen; R Shalgi; L B Frankel; E Leucci; M Lees; M Klausen; Y Pilpel; F C Nielsen; M Oren; A H Lund
Journal:  Cell Death Differ       Date:  2009-08-21       Impact factor: 15.828

6.  Integrated classification of lung tumors and cell lines by expression profiling.

Authors:  Carl Virtanen; Yuichi Ishikawa; Daisuke Honjoh; Mami Kimura; Miyuki Shimane; Tatsu Miyoshi; Hitoshi Nomura; Michael H Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

Review 7.  Management of non-small-cell lung cancer: recent developments.

Authors:  Martin Reck; David F Heigener; Tony Mok; Jean-Charles Soria; Klaus F Rabe
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

8.  MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation.

Authors:  Yong-Xi Song; Zhen-Yu Yue; Zhen-Ning Wang; Ying-Ying Xu; Yang Luo; Hui-Mian Xu; Xue Zhang; Li Jiang; Cheng-Zhong Xing; Yong Zhang
Journal:  Mol Cancer       Date:  2011-01-04       Impact factor: 27.401

9.  The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells.

Authors:  Yang Shi; Can Liu; Xin Liu; Dean G Tang; Junchen Wang
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

Review 10.  MicroRNA-34a: a potential therapeutic target in human cancer.

Authors:  X J Li; Z J Ren; J H Tang
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

View more
  4 in total

Review 1.  Association of sirtuins (SIRT1-7) with lung and intestinal diseases.

Authors:  Yuhan Chen; Di Zhou; Yuan Feng; Bingxin Li; Yong Cui; Gang Chen; Ning Li
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

Review 2.  SIRT6 Widely Regulates Aging, Immunity, and Cancer.

Authors:  Yunjia Li; Jing Jin; Yi Wang
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

3.  miR-34a-5p might have an important role for inducing apoptosis by down-regulation of SNAI1 in apigenin-treated lung cancer cells.

Authors:  Rieko Aida; Keitaro Hagiwara; Kazunori Okano; Kyoko Nakata; Yuho Obata; Takahiro Yamashita; Kaoru Yoshida; Hiromi Hagiwara
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

4.  Characterization of miR-34a-Induced Epithelial-Mesenchymal Transition in Non-Small Lung Cancer Cells Focusing on p53.

Authors:  Masashi Kawami; Shinnosuke Takenaka; Mizuki Akai; Ryoko Yumoto; Mikihisa Takano
Journal:  Biomolecules       Date:  2021-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.